CHRS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
14.3M
+16.2%
12.3M
-3.4%
12.7M
+10.2%
11.6M
+12.8%
10.3M
Cost of Revenue
4.2M
+11.2%
3.8M
-5.7%
4.0M
+8.7%
3.7M
+9.6%
3.4M
Gross Profit
10.1M
+18.5%
8.5M
-2.4%
8.7M
+10.9%
7.8M
+14.4%
6.9M
Operating Expenses
42.4M
-5.0%
44.6M
-18.2%
54.6M
+4.6%
52.2M
-0.3%
52.3M
R&D
21.4M
-0.5%
21.5M
-30.4%
31.0M
+13.7%
27.3M
+3.6%
26.3M
SG&A
21.0M
-9.3%
23.1M
-2.1%
23.6M
-5.3%
24.9M
-4.3%
26.0M
Operating Income
-32331000
+10.6%
-36151000
+21.2%
-45880000
-3.5%
-44333000
+2.5%
-45486000
EBITDA
-31469000
+10.8%
-35270000
+21.6%
-44984000
-3.7%
-43367000
+2.5%
-44470000
Net Income
-20631000
+46.2%
-38327000
-1.8%
-37643000
-5.9%
-35531000
-111.9%
297.8M
EPS (Basic)
$-0.13
+53.6%
$-0.28
+9.7%
$-0.31
+0.0%
$-0.31
-112.1%
$2.57
EPS (Diluted)
$-0.13
+53.6%
$-0.28
+9.7%
$-0.31
+0.0%
$-0.31
-112.1%
$2.57
Shares (Diluted)
154.8M
+13.5%
136.4M
+13.3%
120.4M
+3.6%
116.2M
+0.1%
116.1M
Coherus Oncology (CHRS) โ€” Financials